Oxford BioMedica plc Company Profile (LON:OXB)

Analyst Ratings

Consensus Ratings for Oxford BioMedica plc (LON:OXB) (?)
Ratings Breakdown: 1 Sell Rating(s)
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: GBX 6

Analysts' Ratings History for Oxford BioMedica plc (LON:OXB)
Show:
DateFirmActionRatingPrice TargetActions
3/7/2016N+1 SingerReiterated RatingSellGBX 6View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2015Roth CapitalReiterated RatingBuyGBX 18View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/10/2014Peel HuntUpgradeBuyGBX 3 -> GBX 6View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Oxford BioMedica plc (LON:OXB)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Oxford BioMedica plc (LON:OXB)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Oxford BioMedica plc (LON:OXB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Oxford BioMedica plc (LON:OXB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/25/2016Tallarigo ,LorenzoInsiderBuy63,351GBX 4£2,534.04Tweet This Trade  Share This Trade on StockTwits
6/24/2016Tallarigo ,LorenzoInsiderBuy62,847GBX 4£2,513.88Tweet This Trade  Share This Trade on StockTwits
5/13/2016Diggle ,MartinInsiderBuy42,072GBX 5£2,103.60Tweet This Trade  Share This Trade on StockTwits
5/12/2016Diggle ,MartinInsiderBuy45,428GBX 5£2,271.40Tweet This Trade  Share This Trade on StockTwits
5/5/2016Diggle ,MartinInsiderBuy12,500GBX 6£750Tweet This Trade  Share This Trade on StockTwits
5/4/2016Diggle ,MartinInsiderBuy44,689GBX 6£2,681.34Tweet This Trade  Share This Trade on StockTwits
5/3/2016Diggle ,MartinInsiderBuy317,382GBX 6£19,042.92Tweet This Trade  Share This Trade on StockTwits
4/29/2016Nolan,PeterInsiderBuy359,925GBX 6£21,595.50Tweet This Trade  Share This Trade on StockTwits
4/22/2016Tallarigo ,LorenzoInsiderBuy41,083GBX 6£2,464.98Tweet This Trade  Share This Trade on StockTwits
3/24/2016Tallarigo ,LorenzoInsiderBuy41,550GBX 6£2,493Tweet This Trade  Share This Trade on StockTwits
2/26/2016Diggle ,MartinInsiderBuy29,345GBX 7£2,054.15Tweet This Trade  Share This Trade on StockTwits
2/25/2016Tallarigo ,LorenzoInsiderBuy36,370GBX 7£2,545.90Tweet This Trade  Share This Trade on StockTwits
2/24/2016Diggle ,MartinInsiderBuy46,693GBX 6£2,801.58Tweet This Trade  Share This Trade on StockTwits
7/1/2015Diggle ,MartinInsiderBuy284,439GBX 0.09£256Tweet This Trade  Share This Trade on StockTwits
6/30/2015Diggle ,MartinInsiderBuy775,000GBX 0.09£697.50Tweet This Trade  Share This Trade on StockTwits
6/19/2015Diggle ,MartinInsiderBuy225,000GBX 0.08£180Tweet This Trade  Share This Trade on StockTwits
6/12/2015Martin DiggleInsiderBuy283,978GBX 9.01£25,586.42Tweet This Trade  Share This Trade on StockTwits
6/11/2015Martin DiggleInsiderBuy416,022GBX 9£37,441.98Tweet This Trade  Share This Trade on StockTwits
6/9/2015Daniel SolandInsiderBuy500,000GBX 9.45£47,250Tweet This Trade  Share This Trade on StockTwits
5/21/2015Andrew HeathInsiderBuy100,000GBX 10.60£10,600Tweet This Trade  Share This Trade on StockTwits
5/19/2015Tim WattsInsiderBuy194,174GBX 10.30£19,999.92Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Oxford BioMedica plc (LON:OXB)
DateHeadline
07/21/16 05:59 PMOxford BioMedica plc Declines A lot Today, Is Now One of The Worst Performer - Consumer Eagle
07/12/16 10:02 AMOxford Biomedica (LON:OXB) Analyst Target Prices - FTSE News
07/07/16 05:43 PMOxford Biomedica (LON:OXB) New Price Targets - FTSE News
06/29/16 05:35 PMNew Analyst Ratings For Oxford Biomedica (LON:OXB) - Fiscal Standard
06/25/16 09:26 AMOxford Biomedica (LON:OXB) Broker Roundup - Fiscal Standard
06/07/16 08:26 AMFTSE up on resources after Yellen, follows Europe - Interactive Investor
06/07/16 07:18 AMOxford BioMedica Annual General Meeting - [at noodls] - London, UK - 7 June 2016: Oxford BioMedica plc ('Oxford BioMedica' or 'the Group') (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its ...
06/07/16 02:08 AMMolMed and Oxford BioMedica reviewed and expanded the existing license agreements’ framework - [at noodls] - Microsoft Word - 070616_Termination Agreement_ENG_DEF MolMed and Oxford BioMedica reviewed and expanded the existing license agreements' framework Milan (Italy), June 07, 2016 - MolMed S.p.A. (MLM.MI) ...
06/07/16 01:38 AMEstablishment of a New Non-Exclusive LentiVector® Licence with MolMed - [at noodls] - 07/06/2016 Oxford, UK - 7 June 2016: Oxford BioMedica plc ('Oxford BioMedica' or 'the Group') (LSE:OXB), a leading gene and cell therapy group, today announces that it has signed a new non-exclusive licence ...
06/07/16 01:18 AMNew Non-Exclusive LentiVector Licence with MolMed - [at noodls] - Establishment of a Oxford, UK - 7 June 2016: Oxford BioMedica plc ('Oxford BioMedica' or 'the Group') (LSE:OXB), a leading gene and cell therapy group, today announces that it has signed a new non-exclusive ...
06/06/16 09:24 AMOxford Biomedica (LON:OXB) Morning Trade Volumes - Share Trading News
06/02/16 06:05 PMFTSE stable despite OPEC failing to reach new deal - Interactive Investor - FTSE stable despite OPEC failing to reach new dealInteractive InvestorCell therapy group Oxford Biomedica (OXB) entered a research and development collaboration with Green Cross LabCell to deliver life-saving therapeutics and vaccines, triggering a rise of 3.4% to 5.5p. Pet care specialists Premier Veterinary (PVG ...and more »
06/02/16 08:42 AMFTSE rebounds after oil price recovery - Interactive Investor - FTSE rebounds after oil price recoveryInteractive InvestorCell therapy group Oxford Biomedica (OXB) entered a research and development collaboration with Green Cross LabCell to deliver life-saving therapeutics and vaccines, triggering a rise of 3.9% to 5.53p. Testing kit producer EKF Diagnostics (EKF ...and more »
06/02/16 08:42 AMOxford Biomedica enters R&D collaboration - Stock Market Wire - Oxford Biomedica enters R&D collaborationStock Market WireThe collaboration will focus on identifying and developing gene modified natural killer (NK) cell-based therapeutics for the treatment of life-threatening diseases such as cancer. At 10:27am: (LON:OXB) Oxford BioMedica PLC share price was +0.23p at 5 ...and more »
06/02/16 08:42 AMPublic records - Lancaster Eagle Gazette - Public recordsLancaster Eagle GazetteWestenhouser, Brittany N., 25, 65721 Sam Russell Road, Hamden, convicted of possession of drug abuse instruments, a second-degree misdemeanor. Sentenced to 90 days in jail. Above edited. Fairfield County Municipal Court Traffic Dispositions. For week ...
06/02/16 04:15 AMR&D Partnership with Green Cross LabCell - [at noodls] - Oxford BioMedica and Green Cross LabCell form a Partnership to Develop Gene-modified NK Cell Therapeutics in cancer Unique combination of Oxford BioMedica's LentiVector delivery platform and Green Cross ...
06/02/16 04:05 AMOxford BioMedica and Green Cross LabCell form a Partnership to Develop Gene-modified NK Cell Therapeutics in cancer - [at noodls] - 02/06/2016 Oxford, UK & Seoul, Korea - 2 June 2016: Oxford BioMedica plc ('Oxford BioMedica' or 'the Group') (LSE: OXB), a leading gene and cell therapy group, today announces that it has entered into ...
05/31/16 12:54 AMOxford Biomedica (LON:OXB) Broker Price Targets - Share Trading News - Oxford Biomedica (LON:OXB) Broker Price TargetsShare Trading NewsRecently stock market research analysts have changed their consensus ratings and price targets on shares of Oxford Biomedica (LON:OXB). ... Oxford BioMedica plc is a United Kingdom-based gene and cell therapy research and development business.and more »
02/26/16 09:45 AMDon't You Remember a Comedy Song? - Oxford American - Oxford AmericanDon't You Remember a Comedy Song?Oxford AmericanSong charts were piled next to the mixing console, and an array of keyboard instruments—pianos of grand and electric varieties, a Fender Rhodes organ—stood at the ready. The path to the smaller studio cut through rooms lined with cardboard boxes of ...
02/26/16 09:45 AMDigital PCR to assess gene-editing frequencies (GEF-dPCR) mediated by designer nucleases - Nature.com - Nature.comDigital PCR to assess gene-editing frequencies (GEF-dPCR) mediated by designer nucleasesNature.com11), by permission of Oxford University Press). The first two lines represent the wild-type allele—all other lines represent sequences .... sharing the droplet reader among different laboratories or providing it in a core facility. However, for ...
02/25/16 06:07 AMFull Year 2015 Oxford BioMedica PLC Earnings Release - Before Market Open -
02/13/16 01:24 PMUK Aims at $15B Gene Therapy Industry - Genetic Engineering & Biotechnology News - UK Aims at $15B Gene Therapy IndustryGenetic Engineering & Biotechnology NewsThis partnership includes a licence to OXB technology, as well as OXB in-house manufacture of the lentiviral vector that is used in Novartis' CAR-T cell therapy, CTL019. To meet the needs of this collaboration, Oxford BioMedica has invested ...
02/12/16 01:25 PMOxford Biomedica PLC (OXB) - Today's closing auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual ...
02/11/16 01:16 PMAnalyst Coverage Updates - Oxford Biomedica (LON:OXB) - Risers & Fallers - Analyst Coverage Updates - Oxford Biomedica (LON:OXB)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Oxford Biomedica (LON:OXB). The latest broker reports which are currently outstanding on Wednesday 10th February state 2 analysts have a rating of “strong buy”, 0 analysts ...
01/29/16 11:50 AMFTSE zips up as Japan installs negative interest rate - Stock Market Wire - FTSE zips up as Japan installs negative interest rateStock Market WireStockMarketWire.com - London equities zipped north on opening as traders followed their peers on Wall St and in Asia after Japan installed a negative interest rate of 0.1% in a bid to counter its economic softness by encouraging banks to lend. UK ...
01/29/16 11:50 AMFTSE rising as financials surge on Japan rate call - Interactive Investor - FTSE rising as financials surge on Japan rate callInteractive InvestorOther stocks in the news included St Ives (SIV), Oxford BioMedica (OXB), PCG Entertainment (PCGE), Manx Telecom (MANX), IXICO (IXI), Plant Health Care (PHC), Blenheim Natural Resources (BNR), Challenger Acquisitions (CHAL), Sigma Components ...and more »
01/29/16 01:04 AMOxford BioMedica Announces Initiation of Second CART Programme for Major Pharmaceutical Company - [at noodls] - 29/01/2016 Oxford, UK - 29 January 2016: Oxford BioMedica plc ('Oxford BioMedica' or 'the Group') (LSE: OXB), a leading gene and cell therapy group, announces today that the Group has initiated work on ...
01/27/16 11:16 AMRecent Broker Updates On Oxford Biomedica (LON:OXB) - Risers & Fallers - Recent Broker Updates On Oxford Biomedica (LON:OXB)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Oxford Biomedica (LON:OXB). The latest broker reports which are currently outstanding on Wednesday 27th January state 2 analysts have a rating of “strong buy”, 0 analysts ...
01/13/16 01:07 AMOxford BioMedica Announces Successful MHRA Inspection and Approval to Manufacture at its new Facility in Yarnton, Oxford - [at noodls] - 13/01/2016 - New manufacturing facility fully operational - Creates extra capacity for wholly-owned pipeline, Novartis partnership and other new potential customers Oxford, UK - 13 January 2016: Oxford ...
12/15/15 01:25 AMOxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, is pleased to announce that Dr. Lorenzo Tallarigo will be appointed as Non-Executive Chairman of the Group on 1 February 2016. - [at noodls] - 15/12/2015 Oxford BioMedica plc ('Oxford BioMedica' or 'the Group') (LSE: OXB), a leading gene and cell therapy group, is pleased to announce that Dr. Lorenzo Tallarigo will be appointed as Non-Executive ...
11/18/15 04:59 AMOxford BioMedica to present at the Jefferies 2015 Global Healthcare Conference, London - [at noodls] - Notes to editors: About Oxford BioMedica® Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of ...
10/28/15 02:07 AMGSK Exercises Option on Oxford BioMedica’s LentiVector® Technology Patents - [at noodls] - Notes to editors: About Oxford BioMedica® Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of ...
06/23/15 06:04 AMOxford BioMedica to present at JMP Securities Life Sciences Conference 2015 in New York and to attend ROTH Healthcare Day in London - [at noodls] - Notes to editors: About Oxford BioMedica® Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of ...
05/29/15 01:24 AMOxford BioMedica to Present at Jefferies 2015 Global Healthcare Conference, New York - [at noodls] - 29/05/2015 Oxford, UK - 29 May 2015: Oxford BioMedica plc (LSE: OXB) ('the Group'), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer of Oxford BioMedica, ...
05/13/15 04:27 AMOxford BioMedica Appoints Daniel Soland as Non-Executive Director to the Board - [at noodls] - 13/05/2015 London, UK - 7 May 2015: Oxford BioMedica plc ('Oxford BioMedica' or 'the Group') (LSE:OXB), a leading gene and cell therapy group, today announces the appointment of Daniel Soland as a Non-Executive ...
05/05/15 01:09 AMOxford BioMedica’s Phase I study results with RetinoStat® were selected as a “Hot Topic” at the Association for Research in Vision and Ophthalmology conference in US - [at noodls] - 05/05/2015 Oxford BioMedica's Phase I study results with RetinoStat® were selected as a 'Hot Topic' at the Association for Research in Vision and Ophthalmology conference in US Oxford, UK - 5 May 2015: ...
05/05/15 01:09 AMOxford BioMedica announces that a summary of the 12 month and three year follow up data from the Phase I/II study with ProSavin® was presented at the AANS conference in the US - [at noodls] - 05/05/2015 Oxford, UK - 5 May 2015: Oxford BioMedica plc (LSE: OXB) ('the Group'), a leading gene and cell therapy group, today announces that Professor Stéphane Palfi MD, PhD has presented a summary of ...
05/01/15 02:52 AMOxford BioMedica secures $50 million loan facility with Oberland Capital to support the Group's growth ambitions - [at noodls] - 01/05/2015 Oxford, UK - 1 May 2015: Oxford BioMedica plc (LSE: OXB), ('Oxford BioMedica' or the 'Group') a leading gene and cell therapy Group, today announces that it has secured a $50 million loan facility ...
04/02/15 11:05 AMOxford BioMedica 2014 Annual Report and Accounts & AGM Notification - [at noodls] - 02/04/2015 Oxford BioMedica 2014 Annual Report and Accounts & AGM Notification London, UK - 2 April 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading ...
03/23/15 06:57 AMOxford BioMedica to Present at 3rd Annual Regen Med Investor Day - [at noodls] - 23/03/2015 London, UK - 20 March 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE:OXB), a leading gene and cell therapy company, announces that Dr Paul Blake, Chief ...

Social

About Oxford BioMedica plc

Oxford BioMedica plc logoOxford BioMedica plc is a United Kingdom-based gene and cell therapy research and development business. The Company is lentiviral vector and cell therapy research, development and manufacture. It provides a platform of technologies and capabilities with which it designs, develops and manufactures gene and cell-based medicines. The Company's clinical pipeline is targeting Parkinson's disease, selected cancers and a number of serious eye diseases. The Company has four clinical programs in active development and two other products, including EncorStat and OXB-102, being readied for Phase I/II. EncorStat is being studied for the prevention of corneal graft rejection. OXB-102 is being studied to target Parkinson's disease.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: OXB
  • CUSIP:
Key Metrics:
  • Previous Close: $0.05
  • 50 Day Moving Average: $4.5274
  • 200 Day Moving Average: $5.8420
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $105.31M
  • Current Year EPS Consensus Estimate: $-0.52 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: